Edition:
India

People: Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

37.74USD
13 Sep 2019
Change (% chg)

$-0.41 (-1.07%)
Prev Close
$38.15
Open
$38.27
Day's High
$38.42
Day's Low
$36.68
Volume
430,451
Avg. Vol
200,583
52-wk High
$79.14
52-wk Low
$33.17

Foster-Cheek, Kaye 

Ms. Kaye I. Foster-Cheek is Independent Director of the Company. Ms. Foster has served as a member of our board of directors since December 2014. Ms. Foster has more than 25 years of experience in human resources in the pharmaceutical industry and has been a senior advisor at the Boston Consulting Group since 2014. Previously, she was senior vice president, global human resources at Onyx Pharmaceuticals, Inc., an Amgen, Inc. subsidiary and a biopharmaceutical company, or Onyx from 2010 to 2014. At Onyx, which was acquired by Amgen in 2013, she led all aspects of human resources for U.S. and global operations. Prior to joining Onyx, Ms. Foster was global vice president of human resources and an executive committee member at Johnson and Johnson Corporation, a publicly-traded healthcare company, from 2003 to 2010. Before Johnson and Johnson, Ms. Foster held several senior human resources executive positions with Pfizer Inc., a publicly-traded pharmaceuticals company, supporting its pharmaceuticals businesses in Japan, Asia, Africa, Middle East and Latin America and, notably, led the integration of both the Warner-Lambert and Pharmacia mergers for these regions. Prior to that, she gained 10 years of operational experience within The Yellow Pages. She currently serves on the board of directors of Grail, Inc., a private biotechnology company, and Stanford Health Care, a hospital and healthcare system, and also serves on the board of Spelman College and chairs the Glide Memorial Foundation Board of Trustees. She earned her undergraduate degree at Baruch College of the City University of New York and received her M.B.A. from Columbia University, Graduate School of Business. We believe Ms. Foster’s qualifications to serve on our board of directors include her extensive experience as an executive in the pharmaceuticals industry.

Basic Compensation

Total Annual Compensation, USD 75,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 484,141
Fiscal Year Total, USD 559,141

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --